Description
Sunitinib Malate, sold under the brand name Nitnib, It is licensed for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib Malate is available as a generic medicine in the India.
What is Sunitinib Malate Capsules used for?
It is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. As of August 2021,
How to buy Nitnib, the generic version of sunitinib capsules in India or Globally?
Note: “Nitnib, the generic version of sunitinib capsules” is accessible in India and can be delivered nationwide by Aark Pharmaceuticals. Sunitinib Malate Capsules is a medication that requires a prescription. Sunitinib Malate Capsules is procurable through Aark Pharmaceuticals, based in Delhi, India, who are authorized suppliers of this product nationwide. We have delivered the medications to following cities in India – Bengaluru, Delhi, Ghaziabad, Noida, Gurugram, Chennai, Hyderabad, Mumbai, Pune, Kolkata, and Ahmedabad.. We are committed to delivering 100% authentic products to patients, doctors, and pharmacies. For further details, please contact us at +91-9999156233 or 011-40743520/21/22/23/24 or you can drop an email to us at sales@aarkpharma.com.
List of available and accessible generic brand of Sunitinib Malate Capsules?
Generic brand of Sunitinib Malate available and accessible to patients at an affordable price, at the earliest possible time: Sutent | Tunib | Sunixar | Sutib | Sutinat | Sunishil | Sunimaps | Rcnet | Nitnib
NEWS / Updates
- Sunitinib
- FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma
- Glenmark launches SUTIB (Sunitinib) capsules in India to treat kidney cancer
Written By
Mr. Sandeep Tomar (D. pharma)
Last updated
01 Oct 2024 | 07:25 AM (IST)